Welcome to our dedicated page for Evolv Technologies Holdings SEC filings (Ticker: EVLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Evolv Technologies Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Evolv Technologies Holdings's regulatory disclosures and financial reporting.
Evolv Technologies Holdings, Inc. (EVLV) director Michael Ellenbogen reported an option exercise-and-sale transaction. On August 17, 2026 he exercised 80,752 stock options at an exercise price of $0.24 per share, acquiring an equal number of Class A common shares, then sold 80,752 shares of Class A common stock at a $5.59 weighted average price in open-market or private transactions. After the option exercise, he held 816,262 options directly, and an additional 151,135 shares are held indirectly through the Family Horizon Trust. The sales were effected under a Rule 10b5-1 trading plan entered into on June 12, 2025.
Evolv Technologies Holdings, Inc. (EVLV) received a notice under Rule 144 that director David Mounts Gonzales intends to sell restricted or control securities. The notice lists a proposed sale of 50,000 shares of common stock, with an aggregate market value of $282,543, to be sold through Merrill Lynch in open-market transactions on or about March 26, 2024, on Nasdaq.
Evolv Technologies Holdings, Inc. (EVLV) director Neil Glat purchased 8,500 shares of Class A Common Stock on August 14, 2026 at $5.74 per share in an open-market or private transaction. Following this transaction, he holds 252,100 shares with direct ownership.
Evolv Technologies Holdings, Inc. (EVLV) director Henrik Kuhl reported an open-market purchase of 15,000 shares of Class A Common Stock on 2026-08-14 at a weighted average price of $5.73 per share. These shares are held indirectly by a trust for which he is a co-trustee and beneficiary. Following the transactions reported, he also holds 9,291 shares directly.
Evolv Technologies Holdings, Inc. reported higher revenue and narrower losses for the three and six months ended June 30, 2026. Total revenue for the first half of 2026 was $90.1 million, up from $64.6 million, driven mainly by growth in subscription revenue to $47.9 million and product revenue to $22.5 million. Gross profit rose to $45.6 million, reflecting scale across product, subscription, and services.
Operating expenses for the first half were $64.6 million versus $67.3 million, with lower general and administrative costs and no 2025‑type restructuring charges, leading to a reduced loss from operations of $19.0 million. Net loss for the first half improved to $14.3 million from $42.2 million, or $0.08 per share versus $0.26. Operating activities generated $8.7 million of cash, compared with a small outflow a year earlier.
As of June 30, 2026, Evolv held $62.6 million in cash, cash equivalents and marketable securities, with $30.0 million of term debt outstanding and additional borrowing capacity under its $75.0 million Senior Secured Credit Facilities. Deferred revenue was $92.2 million and remaining performance obligations totaled $312.6 million, supporting future subscription visibility. The company remains in compliance with its ARR and liquidity covenants but continues to expect losses as it invests for growth and manages ongoing class‑action and derivative settlements and an SEC inquiry.
Evolv Technologies Holdings reported strong second-quarter 2026 results, with revenue of $43.8 million, up 34% year-over-year, and Annual Recurring Revenue of $132.7 million, up 20%. The company added 70 new customers and ended the quarter with Remaining Performance Obligation of $312.6 million.
Net loss narrowed to $(9.3) million, or $(0.05) per share, from $(40.5) million a year earlier, while Adjusted EBITDA improved to $4.4 million from $2.1 million, yielding a 10.1% Adjusted EBITDA margin. For the first six months of 2026, revenue was $90.1 million, up 40% year-over-year, with Adjusted EBITDA of $8.4 million.
The company ended June 30, 2026 with $63.4 million in cash, cash equivalents, marketable securities, and restricted cash, up $2.3 million sequentially, and generated $8.7 million of operating cash flow in the first half. Management raised 2026 guidance, now expecting total revenue of $180–$185 million and ending ARR of $148–$150 million, and targets Adjusted EBITDA of $15–$16 million with margins in the high single digits.
Evolv Technologies Holdings, Inc. reported that the U.S. District Court for the District of Massachusetts has preliminarily approved a global settlement of multiple stockholder derivative matters brought on the Company’s behalf. The settlement, documented in an August 5, 2026 stipulation, covers the consolidated federal derivative action, two related Delaware Court of Chancery derivative actions, and a stockholder litigation demand.
The settlement provides for a package of corporate governance reforms, including amendments to the Audit Committee Charter, Marketing Policy, Disclosure Committee Charter, and Corporate Governance Guidelines, creation of a management-level compliance committee, and enhanced roles for the General Counsel in legal and compliance oversight. These reforms will be implemented within 30 days of the settlement’s effective date and maintained for five years. The settlement does not require any payment by Evolv; plaintiffs’ attorneys’ fees and expenses of $1,275,000 are to be paid by the Company’s insurers. A settlement hearing is scheduled for October 21, 2026, and current stockholders as of August 5, 2026 may object or be heard subject to specified procedures.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 13,440,609 shares of EVOLV TECHNOLOGIES HOLDINGS INC Class A stock. This represents 7.5% of the class. BlackRock reports sole voting power over 13,159,037 shares and sole dispositive power over 13,440,609 shares, with no shared voting or dispositive power.
BlackRock notes that various underlying clients and investors have economic rights to dividends and sale proceeds, but no single such person has more than five percent of the outstanding common shares.
Michael Ellenbogen, a director of Evolv Technologies Holdings, Inc., exercised stock options for 80,745 shares of Class A Common Stock at $0.24 per share and on the same date sold 80,745 shares at a weighted-average price of $5.94 under a Rule 10b5-1 trading plan. Following these transactions, he holds 2,083,961 shares directly, 151,135 shares indirectly through the Family Horizon Trust, and 897,014 stock options expiring on September 13, 2027.
Evolv Technologies Holdings, Inc. had its warrants removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 under Section 12(b) of the Securities Exchange Act of 1934, stating that the exchange and the issuer complied with 17 CFR 240.12d2-2(b) and 12d2-2(c).